FNP: Hyperlipidemia

Under coding guidelines, the use of an independent historian combined with ordering or reviewing at least two unique tests easily meets the criteria for moderate data complexity. Low data complexity requires only two tests or an independent historian, but not both categories simultaneously. High data complexity requires the independent interpretation of tests or discussion of management with external providers, which did not occur here. Straightforward data involves minimal or no test review, ignoring the comprehensive workup performed.

The traditional Argentine diet heavily features grilled red meats. A culturally sensitive approach involves negotiating acceptable alternatives that fit the cultural context, such as substituting high-fat red meats with leaner proteins like poultry and fish prepared using similar traditional grilling methods. Insisting on a strict plant-based regimen or restricting red meat to once a month is overly rigid and culturally discordant. Advising him to boil meats ruins the traditional culinary experience and ensures non-adherence.

Simvastatin 20 mg is a moderate-intensity statin, which is expected to lower LDL by 30 to 49 percent. A drop from 150 mg/dL to 100 mg/dL is exactly a 33% reduction, indicating an appropriate and successful therapeutic response. Option A is correct because the medication is working exactly as intended for her risk category. Option B is incorrect because moderate-intensity statins do not target a 50% reduction. Options C and D are incorrect because they represent unnecessary pharmacological escalations for a primary prevention patient who is already meeting her expected risk-based therapeutic outcome without adverse effects.

The patient is experiencing a classic prescribing cascade where amlodipine caused peripheral edema, leading to the inappropriate addition of furosemide. The diuretic then caused urinary incontinence and orthostatic hypotension, increasing his fall risk. Discontinuing the furosemide and decreasing or stopping the amlodipine directly addresses the root cause of the symptoms without adding further anticholinergic burden. Option B worsens polypharmacy by treating an adverse drug effect with oxybutynin, which can cause severe confusion in frail elders. Option C inappropriately targets the ACE inhibitor rather than the calcium channel blocker, which is the actual culprit for the peripheral edema. Option D focuses on diagnostic testing but delays the immediate and necessary pharmacotherapeutic intervention required to stabilize this frail patient.

Mild, asymptomatic elevations in transaminases are a known, often transient effect of statin therapy. Current guidelines suggest that unless the liver enzymes exceed three times the upper limit of normal or the patient develops symptoms of hepatic injury, the best approach is to continue the medication and monitor. Continuing the medication and rechecking labs aligns perfectly with this standard. Discontinuing the medication immediately is an overreaction to a mild, asymptomatic elevation and unnecessarily halts cardiovascular risk reduction. Decreasing the dose or switching to a different statin is premature because these mild elevations frequently resolve on their own without any intervention. You only need to alter the regimen if the transaminase elevation persists or worsens significantly on subsequent testing.